111 Inc. (YI) is a Retail-Drug Stores and Proprietary Stores company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for YI, including 1 leadership change and 1 SEC filing. The most recent was published Oct 26, 2026.
Price$3.02-0.81 (-21.02%)
2026-08-102026-11-10
Financial highlights
Full financials- Revenue, FY2025
- CN¥12.56B
- Revenue growth
- -12.8%
- Net income, FY2025
- -CN¥66.39M
- Net margin
- -0.5%
- Free cash flow, FY2025
- CN¥114.69M
- Cash
- CN¥510.97M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks19-50%
2026-05-172026-11-08
Mix1090d
- SEC Filings4(40%)
- Other3(30%)
- Insider2(20%)
- Leadership1(10%)
Activity · 52 weeks3417 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 6-K filed by 111 Inc.6-K - 111, Inc. (0001738906) (Filer)
- PR111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special CommitteeSHANGHAI, Oct. 26, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors ("the Board"), has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary, non-binding proposal letter dated September 16, 2026 (the "Proposal")
- INSIDERDirector Chen Yang Luke was granted 594,222 units of RSUs and sold $37,622 worth of RSUs (180,880 units at $0.21) (SEC Form 4) to cover taxes4 - 111, Inc. (0001738906) (Issuer)
- SECSEC Form 6-K filed by 111 Inc.6-K - 111, Inc. (0001738906) (Filer)
- PR111, Inc. Announces Establishment of the Special CommitteeSHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, has been established by the Company's Board of Directors to consider and evaluate the previously announced preliminary, non-binding proposal letter dated September 16, 2026 (the "Proposal") as well as other potential strategic alternatives that the Company may pursue. The Board cautions the Company's shareholders and others considering tra
- INSIDERDirector Chen Yang Luke sold $30,760 worth of RSUs (142,760 units at $0.22) and was granted 594,222 units of RSUs (SEC Form 4) (for tax liability)4 - 111, Inc. (0001738906) (Issuer)
- SECSEC Form 6-K filed by 111 Inc.6-K - 111, Inc. (0001738906) (Filer)
- SECSEC Form 6-K filed by 111 Inc.6-K - 111, Inc. (0001738906) (Filer)
- PR111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the CompanySHANGHAI, Sept. 17, 2026 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dated September 16, 2026 jointly submitted by Dr. Gang Yu, co-founder and co-chairman of the Company, Mr. Junling Liu, co-founder, co-chairman and chief executive officer of the Company (collectively, the "Co-Founders") and Huadeng Tech BioArray Ventures Ltd (the "Sponsor," and together with the Co-Founders, the "Buyer Group"), proposing to acquire all of outstanding Class A ordinary shares (the "Class A
- PR111, Inc. Announces Second Quarter 2026 Unaudited Financial ResultsTransition from An Asset-Heavy Business Model to An Asset-Light Business ModelOngoing Investment and Adoption of AI Agents Making Workforce Streamlining PossibleNet Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-YearTotal Marketplace (MP) Service Revenue Increased by 18.2% Year-over-Year for the First Half of 2026Fulfillment Expenses as a Percentage of Revenue Improved by 5 Basis Points Year-over-YearSHANGHAI, Sept. 17, 2026 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downst
- INSIDERDirector Chen Yang Luke was granted 594,222 units of RSUs and sold $22,840 worth of RSUs (98,760 units at $0.23) (SEC Form 4) to cover withholding tax4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Sun Jian David was granted 810,271 units of RSUs and sold $92,749 worth of RSUs (397,060 units at $0.23) (SEC Form 4) (withholding tax)4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Sun Jian David was granted 810,271 units of RSUs and sold $79,225 worth of RSUs (338,260 units at $0.23) (SEC Form 4) (tax liability)4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Sun Jian David was granted 810,271 units of RSUs and sold $53,672 worth of RSUs (227,160 units at $0.24) (SEC Form 4) to satisfy tax liability4 - 111, Inc. (0001738906) (Issuer)
- SECSEC Form 6-K filed by 111 Inc.6-K - 111, Inc. (0001738906) (Filer)
- PR111, Inc. Announces First Quarter 2026 Unaudited Financial ResultsContinuing Transition toward a More Asset-Light and Operationally Efficient Business ModelNet Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-YearTotal Marketplace (MP) Service Revenue Increased by 24.7% Year-over-YearFulfillment Expenses as a Percentage of Revenue Improved by 10 Basis Points Year-over-YearSHANGHAI, June 4, 2026 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March
- INSIDERDirector Luo Jun Justin was granted 810,271 units of RSUs and sold $25,516 worth of RSUs (99,720 units at $0.26) (SEC Form 4) to cover taxes4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Sun Jian David was granted 810,271 units of RSUs and sold $25,516 worth of RSUs (99,720 units at $0.26) (SEC Form 4) to satisfy withholding obligation4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Chen Yang Luke was granted 594,222 units of RSUs and sold $1,239 worth of RSUs (4,840 units at $0.26) (SEC Form 4) to satisfy withholding tax4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Teo Nee Chuan gave a grant of 811,889 units of RSUs, increasing direct ownership by 1,931% to 811,889 units (SEC Form 4)4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Chen Yang Luke gave a grant of 594,222 units of RSUs, increasing direct ownership by 135% to 594,222 units (SEC Form 4)4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Luo Jun Justin gave a grant of 810,271 units of RSUs, increasing direct ownership by 2,106% to 810,271 units (SEC Form 4)4 - 111, Inc. (0001738906) (Issuer)
- INSIDERDirector Sun Jian David gave a grant of 810,271 units of RSUs, increasing direct ownership by 2,106% to 810,271 units (SEC Form 4)4 - 111, Inc. (0001738906) (Issuer)
- SECSEC Form 20-F filed by 111 Inc.20-F - 111, Inc. (0001738906) (Filer)
- SECSEC Form 6-K filed by 111 Inc.6-K - 111, Inc. (0001738906) (Filer)
YI FAQ
10 questionsWhat does 111 Inc. do?
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact...What is the latest news on YI?
In the last 30 days Quantisnow tracked 2 wire items for YI: 1 leadership change and 1 SEC filing. The most recent was published on October 26, 2026.What is YI revenue?
111 Inc. (YI) reported CN¥12.56B of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 12.8% from the year before.Is YI profitable?
No. 111 Inc. reported a net loss of CN¥66.39M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does YI have?
111 Inc. reported CN¥510.97M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does YI stock trade?
111 Inc. (YI) is listed on NASDAQ.What sector and industry is YI in?
111 Inc. operates in the Consumer Staples sector, Retail-Drug Stores and Proprietary Stores industry.When did 111 Inc. go public?
111 Inc. (YI) completed its IPO in 2018.What companies are similar to YI?
Notable peers in the same industry include TUYA (Tuya Inc.), YSG (Yatsen Holding Limited), JWEL (Jowell Global Ltd.), BZUN (Baozun Inc.). Compare YI side-by-side with any of them on Quantisnow.How can I track YI on Quantisnow?
Quantisnow aggregates 111 Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YI to receive live email and push alerts on every new disclosure.